Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Angeliq Micro
- Development stage
- Phase 4
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Angeliq Micro (BAY86-4891) is a low-dose, continuous combined oral hormone therapy (HT) developed by Bayer for the treatment of vasomotor symptoms associated with menopause in postmenopausal women. It consists of a combination of 17β-estradiol, a synthetic estrogen, and drospirenone, a fourth-generation progestin with anti-mineralocorticoid and anti-androgenic properties. The estradiol component replaces declining endogenous estrogen levels to alleviate climacteric symptoms like hot flushes, while drospirenone is included to protect the endometrium against estrogen-induced hyperplasia. The ultra-low dose formulation (0.5 mg estradiol / 0.25 mg drospirenone) is designed to provide efficacy with an improved safety and tolerability profile, particularly regarding bleeding patterns and endometrial safety.
- Brand names
- Angeliq MicroAngeliq
- Other names
- drospirenone + estradiolestradiol + drospirenone17β-estradiol + drospirenone
02
Targets
AR (Adrenergic receptors)ER (Estrogen receptor)MR (Mineralocorticoid receptor)PR (Progesterone receptor)
Beyond the preview
Go deeper on Angeliq Micro.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Angeliq Micro.